MaxCyte, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
MaxCyte, Inc. (MXCT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $956.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-13
- MaxCyte, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- MaxCyte, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $956.00K.
- MaxCyte, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $956.00K.
- MaxCyte, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.78M, a 67.46% decline from fiscal 2022.
- MaxCyte, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $5.48M, a 13.97% increase from fiscal 2021.
- MaxCyte, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $4.80M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $956.00K 10-K · filed 2026-03-25 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $956.00K 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $956.00K 10-Q · filed 2026-05-13 | |||
| 2023-12-31 | $1.78M 10-K · filed 2025-03-11 | |||
| 2022-12-31 | $5.48M 10-K · filed 2024-03-12 | $5.48M 10-K · filed 2023-03-15 | ||
| 2021-12-31 | $4.80M 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |